Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TFC-039
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Recipient : Sirona Biochem Corp
Deal Size : Undisclosed
Deal Type : Partnership
Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals
Details : Under the agreement, Wanbang obtained the rights to develop the SGLT2 inhibitor, TFC-039 as a diabetes treatment in China and Sirona retained the global rights. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 23, 2022
Lead Product(s) : TFC-039
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Recipient : Sirona Biochem Corp
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Lidocaine,Prilocaine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Recipient : Regent Pacific
Deal Size : $4.0 million
Deal Type : Licensing Agreement
Regent Pacific's Strategic Partner Receives Approval from NMPA to Submit IND Application
Details : Under the License Agreement Regent Pacific is now entitled to receive a payment of approximately HK$6.24 million from Wanbang Pharmaceutical, which is payable within 30 business days. NMPA will now formally review Senstend™ for Clinical Trial Approval.
Product Name : Senstend
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 02, 2020
Lead Product(s) : Lidocaine,Prilocaine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Regent Pacific
Deal Size : $4.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Dun Ye Guan Xin Ning
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Recipient : Peking University First Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Dun Ye Guan Xin Ning Tablet in Patients With Stable Angina Pectoris
Details : Dun Ye Guan Xin Ning is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Coronary Disease.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
June 23, 2017
Lead Product(s) : Dun Ye Guan Xin Ning
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Recipient : Peking University First Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
